Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
ACADIA Pharmaceuticals Inc. (ACAD) had Return on Tangible Equity of 34.96% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$1.07B |
|
$391.00M |
|
$89.00M |
|
$982.51M |
|
$966.69M |
|
$104.81M |
|
$34.09M |
|
$138.90M |
|
$138.90M |
|
$391.00M |
|
$391.00M |
|
$391.00M |
|
$391.00M |
|
$104.81M |
|
$111.15M |
|
168.36M |
|
169.92M |
|
$2.32 |
|
$2.30 |
|
| Balance Sheet Financials | |
$1.06B |
|
$7.51M |
|
$502.08M |
|
$1.56B |
|
$277.11M |
|
-- |
|
$59.69M |
|
$336.81M |
|
$1.23B |
|
$1.12B |
|
$1.23B |
|
170.31M |
|
| Cash Flow Statement Financials | |
$109.84M |
|
$-302.56M |
|
$49.88M |
|
$328.36M |
|
$185.54M |
|
$-142.82M |
|
$52.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.83 |
|
-- |
|
-- |
|
-- |
|
-- |
|
91.69% |
|
9.78% |
|
9.78% |
|
10.37% |
|
12.96% |
|
36.49% |
|
$105.15M |
|
-- |
|
-- |
|
-- |
|
0.69 |
|
2.57 |
|
7.23 |
|
50.49 |
|
31.86% |
|
|
Return on Tangible Equity |
34.96% |
25.00% |
|
31.86% |
|
$7.21 |
|
$0.62 |
|
$0.65 |
|